Under vurderingen af lægemidlet trak virksomheden trak sin ansøgning om brug af Xiliarx som enkeltmiddelbehandling og som tillægsbehandling til insulin tilbage.
The company withdrew its application for the use of Xiliarx on its own and as an add-on to insulin during the assessment of the medicine.